Your session is about to expire
← Back to Search
CIML NK Cells for Leukemia
Study Summary
This trial is studying CIML NK cells plus IL-2 in treating patients with acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms who have relapsed after stem cell transplantation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had severe graft-versus-host disease or it's currently active and needs treatment.I haven't taken any systemic treatments for GVHD in the last 4 weeks.I can take care of myself and do some daily activities.I do not have autoimmune diseases like Crohn's, lupus, or rheumatoid arthritis, but Hashimoto's thyroiditis is okay.My disease is still present after stem cell transplant and it's been over 2 months.I have received a solid organ transplant or a stem cell transplant.I haven't taken high-dose steroids or certain immune system drugs for 4 weeks.I haven't taken experimental drugs, immunotherapy, or had severe side effects from past treatments recently.I am not pregnant or capable of becoming pregnant.I agree to use birth control during and up to 4 months after the study.My bone marrow is less than 80% involved and I may be taking specific medications to control my condition.My original stem cell donor is available and willing to donate again without mobilization.I do not have active, uncontrolled hepatitis B or C, HIV, or HTLV-1.I have not had a donor lymphocyte infusion in the last 8 weeks.My cancer has spread to areas like the brain, eyes, or testes.You have had allergic reactions to drugs that are similar to IL-2 or other drugs used in this study.I am not HIV-positive.My AML, MDS, or MPN has returned or persisted after a transplant.I can understand and am willing to sign the consent form.I had cancer before, but it's been in complete remission for 2+ years or was a non-spreading skin cancer treated within 2 years.I am healthy enough for the treatment, or have recovered from a serious illness recently.I am not pregnant or breastfeeding.I am 12 years old or older.I do not have any serious illnesses that could interfere with the study.
- Group 1: CIML NK
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of patients participating in this clinical trial?
"Affirmative. Per the details published on clinicaltrials.gov, this research project is actively recruiting participants and was last updated on June 15th 2022. 50 individuals shall be sourced from two sites for inclusion in the study; it first opened to applicants back on August 31st 2019."
What have been the major findings of research concerning CIML NK?
"At present, 889 live studies are being conducted on CIML NK. Out of these research operations, 161 have reached the advanced Phase 3 stage. While a majority of trials occur in Philadelphia, Pennsylvania - 28443 sites around the world are running experiments with this drug treatment."
What evidence exists to demonstrate the safety of CIML NK for patients?
"There is only a small amount of evidence attesting to the safety and efficacy of CIML NK, thus it received an assessment of 1."
What symptoms have been addressed most often with CIML NK therapy?
"CIML NK is a popular medication for the treatment of multiple sclerosis, but it may also be efficacious in treating conditions such as mixed-cell type lymphoma, leukemia, myelocytic acute and retinoblastoma."
Are there any available openings for participants in this research?
"Affirmative. Clinicaltrials.gov suggests that this research study is still searching for participants, which was first made known on August 31st 2019 and has been revised as of June 15th 2022. The trial necessitates 50 people to be enrolled from two separate medical sites."
Share this study with friends
Copy Link
Messenger